A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Since a proportion of patients with Acute Viral Hepatitis-B develop severe hepatitis and
fulminant hepatic failure, it is logical to believe that a rapid reduction in the HBV DNA
levels by using antiviral agents could result in a less intense host response against the
hepatitis B virus. However, the experience with lamivudine treatment of immunocompetent
patients with AVH-B is limited.The aim of the present study was to evaluate the efficacy,
utility and safety of lamivudine in treating immunocompetent patients with AVH-B.